Special Section on Drug Delivery Technologies—Minireview

Smart Drug Release from Medical Devices

Carmen Alvarez-Lorenzo and Angel Concheiro

Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia, and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain

Received February 8, 2019; accepted April 1, 2019

ABSTRACT

Medical devices are becoming key players on health monitoring and treatment. Advances in materials science and electronics have paved the way to the design of advanced wearable, insertable, and implantable medical devices suitable for the prevention and cure of diseases and the physical or functional replacement of damaged tissues or organs. However, intimate and prolonged contact of the medical devices with the human body increases the risks of adverse foreign-body reactions and biofilm formation. Drugs can be included in/on the medical device not only to minimize the risks but also to improve the therapeutic outcomes. Drug-eluting medical devices can deliver the drug in the place where it is needed using lower doses and avoiding systemic effects. Drug-device combination products that release the drug following preestablished rates have

already demonstrated their clinical relevance. The aim of this mini-review is to bring attention to medical devices that can actively regulate drug release as a function of tiny changes in their environment, caused by the pathology itself, microorganisms adhesion or some external events. Thus, endowing medical devices with stimuli-responsiveness should allow for precise, on-demand, regulated release of the ancillary drugs to expand the therapeutic performance of the medical device and also should serve as a first step to offer personalized solutions to each patient. Main sections deal with smart drug-eluting medical devices that are sensitive to infection-related stimuli, natural healing processes, mechanical forces, electric fields, ultrasound, near-infrared radiation, or chemicals such as vitamin C.

Introduction

Human health quality has undergone an unprecedented improvement in the last century, which is evidenced as the decrease in the death ratio at infancy and the much longer life expectation. Such health achievements are mainly associated with better feeding, the prevention of pandemic illnesses through worldwide-distributed vaccines, advances in less-invasive surgical maneuvers under clean conditions, and the development of treatments that turn incurable illnesses into chronic ones or that go to the roots of the illness to reverse it (Fielding, 1999). The strong evolution of pharmacologic and radiotherapy approaches has been critical for these achievements (Heath and Colburn, 2000; Bhide and Nutting, 2010). At present, most health-monitoring systems and treatments involve the use of precisely designed medical devices.

According to the U.S. Food and Drug Administration (FDA), medical devices comprise a large variety of instruments,

apparatuses, implants, and in vitro reagents intended for the diagnosis, prevention, or cure of diseases or to affect the structure or any function of the body, which do not achieve any of their primary intended purposes through chemical action. Such (bio)chemical action has been restricted to the medications (FDA, 2018b). Flash glucose monitoring systems; versatile stents that allow simultaneous diagnostic and therapeutic maneuvers, particularly in the gastrointestinal organs; devices that trap blood clots and help reduce stroke risk; noninvasive devices that allow assessment of head injuries at point-of-care; test devices for solid tumors that help make immunotherapy decisions; advanced dermal regeneration matrices that can regenerate native tissues, particularly intended for diabetic ulcers; breast imaging devices that offer high-contrast, real, three-dimensional (3D) images of all structures; implantable drug infusion pumps that precisely deliver the correct amount of drug needed at each time; and sensors inside oral medicines that track whether the medication has been taken and send the information to a smartphone app or web portal, among others are not a dream. All these are already counted in the list of the most innovative medical devices (Kirsh, 2018). Advances in materials sciences and electronics are behind sophisticated, wearable medical devices that allow continuous monitoring of

This work was funded by MINECO [SAF2017-83118-R], Agencia Estatal de Investigación (AEI) Spain, Xunta de Galicia [Grupo de Referencia Competitiva ED431C 2016/008; Agrupación Estratégica en Materiales-AEMAT ED431E 2018/08], and FEDER (Spain).
<https://doi.org/10.1124/jpet.119.257220>

ABBREVIATIONS: 3D, three dimensional; DES, drug-eluting stents; FDA, U.S. Food and Drug Administration; NIR, near-infrared; NSAIDs, nonsteroidal anti-inflammatory drugs; PAA, poly(acrylic acid); PLGA, poly(lactic-co-glycolic acid); PNIPAAm, poly(*N*-isopropylacrylamide).

certain physiologic functions for diagnosis or of pharmacologic levels of therapeutic substances for efficient personalized treatments (Yetisen et al., 2018).

Despite these achievements, the use of medical devices carries the intrinsic risk of causing adverse foreign-body reactions or other side effects from the adherence of the user's proteins and cells or from the proliferation of microorganisms (Anderson, 2001). Medical devices are categorized into three classes according to their intended use and the risk they may pose to the patient or the user. Invasiveness increases these risks, so devices intended to penetrate the body and remain in contact with or inside the body for prolonged time should follow very strict rules. Yet adverse events remain common; for example, restenosis associated with vascular stents (Iqbal et al., 2013), posterior capsule opacification associated with intraocular lenses after cataracts surgery (Nibourg et al., 2015), or biofilm formation on urinary catheters, bone prostheses, or central venous catheters with the subsequent infection spreading in host tissues (De Angelis et al., 2010; Wallace et al., 2017) affect a relevant percentage of patients and have had a strong economic impact on health care systems.

The evolution of materials science has been enormous in improving the performance and safety of medical devices (Teo et al., 2016), but in most cases the risks have been strongly minimized by combinations with the right drugs (Couto et al., 2012; Alvarez-Lorenzo et al., 2017). Systemic treatments prescribed to patients wearing medical devices still have relevant untoward effects—for instance, the risk of respiratory and gastrointestinal disorders associated with post-implantation pain and inflammation treatment, bleeding events due antithrombosis therapy after the implantation of stents or other blood-contact biomaterials, or emerging microbial resistance from using prophylactic antimicrobial therapy (Bhusal et al., 2016; Reviakine et al., 2017).

As an alternative, the advantages of incorporating the drug on/in the medical device itself are clear. The drug is delivered in the place where it is needed (usually a place that is hardly accessible through a systemic route), which lowers the amount required (lower dilution, fewer barriers, and slower clearance); the device itself may adjust the release to the therapeutic demands. This strategy increases both efficiency and safety, and it is not dependent on patient compliance (Wenke and Guelcher, 2011; Bhusal et al., 2016; Cyphert and von Recum, 2017; Sanchez-Rexach et al., 2017). However, endowing medical devices with the drug-delivery performance is not a simple task because most materials do not uptake sufficient amounts and/or do not regulate the release according to the therapeutic needs (Alvarez-Lorenzo and Concheiro, 2013; Lee et al., 2017).

The increasing demand for medical devices with improved or even novel performance parameters has blurred the boundary between medicaments and medical devices. Historically, pharmaceutical companies have been drug-centric and the medtechs have been technology device-centric; however, both sectors have joined in offering patient-centric approaches with a strong life-changing impact. Indeed, the definition of medical device provided by the World Health Organization (WHO) is now wider: even if a medical device does not achieve its primary mode of action by pharmacologic, immunologic, or metabolic means, it may be assisted in its intended function by such means (WHO, 2018). In this regard, combination products have appeared as a novel, broad regulatory category, which includes

any binary or ternary combination of a drug, biologic product, and/or device (Alvarez-Lorenzo and Concheiro, 2013; FDA, 2018c).

Drug-device combination products in which the device is responsible for the primary mode of action—it makes the greatest contribution to the overall intended therapeutic effects, while the drug performs as an ancillary medicinal substance—are commonly known as drug-eluting devices or drug-enhanced device products. Drug-eluting stents (DES) are a clear example of the strong research in this field (Huang et al., 2014). The use of coronary bare-metal stents remarkably reduced the mortality associated with coronary artery diseases, but the risk of failure due to in-stent restenosis was approximately 30% patients (Holmes, 2003). The first-generation DES, introduced in 2002, relied on antiproliferative agents incorporated into a polymer coating that regulated the release. This product can be considered as the first regulated drug-medical device combination product (Simard et al., 2014).

Nevertheless, coatings with nonbiodegradable polymers (first generation) or thinner inorganic composites (second generation) trigger inflammatory responses that cause late stent restenosis. Biodegradable coatings (third generation) may attenuate some of the untoward events, but the polymer itself may still be responsible for adverse immune reactions. Thus, current efforts are focused on polymer-free stents that can still regulate drug release through a very precise design of the topology of the stent surface and a slowdown of intrinsic solubility rate of the drug (Acharya and Park, 2006; Sanchez-Rexach et al., 2017; Kommineni et al., 2018; Konishi et al., 2018). Some of these fourth-generation DES as well as several other drug-device combinations products are already in the market (Table 1).

It should be noted that the drug can be included in the matrix of the device during fabrication, layered as a coating in a subsequent step, or placed into a specific reservoir. The two latter options are preferred for labile ancillary drugs or for matrices whose mechanical properties may be affected if the drug is incorporated (Raval and Parikh, 2010).

This mini-review revisits the recent advances in medical devices that can actively regulate drug release as a function of tiny changes in their environment caused by the progression/remission of the pathology, the growth of microorganisms, or some external events. Thus, in contrast to medical devices (such as stents) that release the drug in a sustained, preestablished rate, as reported elsewhere (Zilberman and Elsner, 2008; Concheiro and Alvarez-Lorenzo, 2013), the following sections deal with medical devices endowed with stimuli-responsiveness as a tool for efficient drug loading and elution as a function of specific demands.

Medical devices made of materials that can modify their properties as a function of stimuli coming from inside or outside the body have been attracting a great deal of attention. As a relevant example, strong efforts are being made in the design of 3D architectures for implantation with properties that evolve over time. These four-dimensional systems may offer advantages in terms of shape-memory that facilitates the implantation through minimally invasive maneuvers and adapts to the required shape once placed in the patient (Oliver et al., 2016; Antony et al., 2017). Similarly, hydrogels, which undergo phase volume transitions (e.g., modify the swelling) as a function of tiny changes in certain variables in

TABLE 1

Common examples of commercially available devices coated/impregnated or otherwise combined with drugs according to FDA classification of combination products. The device has an additional function in addition to delivering the drug (FDA, 2018c).

Drug-Eluting Medical Device	Example	Reference
Drug pills embedded with sensors	Drug-loaded tablet-like device for monitoring medication adherence, mainly intended for mental disorders (Abilify MyCite) and cancer (clinical trials)	FDA, 2017
Drug-eluting stents	Sirolimus, paclitaxel, everolimus, zotarolimus, or biolimus included on the stent surface to minimize restenosis and/or prevent late thrombosis	Lee and de la Torre Hernandez (2018)
Drug-eluting leads	Steroid-coated pacemaker electrodes to prevent inflammatory mediators release and myocardial damage	Matsuhisa et al. (2014); McVenes and Stokes (2016)
Condoms with spermicide	Coatings of nonoxonyl-9 to increase contraceptive effectiveness	FDA, 2018a
Dental floss with fluoride	Fluoride incorporated into the wax for caries prevention	Flatt et al. (2008)
Antimicrobial coated catheters/sutures	Silver and a variety of antimicrobial agents incorporated into the matrix or as coatings of urinary catheters, central venous catheters, sutures, or endotracheal tubes	Tummalapalli et al. (2016); Singha et al. (2017)
Bone cements with antibiotics	Vancomycin, aminoglycosides, β -lactams, lipopeptides, oxazolidinones, and antifungals compounded extemporaneously with the cement, or the cement provided preloaded with the drug	Athans et al. (2017)

PAA, poly(acrylic acid); PLGA, poly(lactic-co-glycolic) acid.

the body, have found application as chemical sensors and soft actuators (Ikeda et al., 2014; Yoshida et al., 2018).

A step farther is to exploit such stimuli-responsiveness for a precise, on-demand regulated release of the ancillary drugs to expand the therapeutic performance of the medical device and attenuate its risks. Smart drug delivery by means of nanocarriers has been widely reported (Alvarez-Lorenzo and Concheiro, 2014), but stimuli-responsive drug release from medical devices has yet to be fully explored (Alvarez-Lorenzo and Concheiro, 2013). Smart drug eluting devices may offer novel ways of addressing unmet clinical needs and may open the path to truly custom/personalized medical devices (Fig. 1).

Infection-Responsive Antimicrobials-Eluting Medical Devices. Medical devices are prone to microorganism contamination not only before implantation via contact with the skin or mucosa of the patient but also after implantation if latent microorganisms migrate from infection focuses in other parts of the body (Percival et al., 2015). The settling of microorganisms on a medical device usually evolves as biofilm formation: a highly structured community undergoes phenotypic changes mediated by a quorum sensing communication mechanism that makes the microorganisms highly resistant

to conventional antimicrobial agents (Remy et al., 2018). Thus, once a biofilm has formed, its eradication is difficult; the risk of it spreading to other tissues through bloodstream is high and could compromise the patient's life. Implantable medical devices are responsible of almost 50% of nosocomial infections (WHO, 2011).

Even in a less acute situation, biofilm formation may compromise the mode of action of the medical device; for example, biofilms may block catheter flow (Jones et al., 2005) or delay the natural healing of wounds if they colonize either the suture or the adjacent tissue (Hong et al., 2018). Various bone cements that incorporate antimicrobial agents are already on the market, but they usually release most of their drug on the first day, followed by sustained elution of sometimes subtherapeutic doses, which may compromise the prophylactic role (King et al., 2018).

Because the prolonged release of antimicrobials may cause adverse events and favor antimicrobial resistance (McLaren, 2004), a variety of stimuli-responsive polymers have been tested for the development of drug nanocarriers capable of site-specific delivery of antimicrobial agents in the infection location. More recently, they have been used to adorn medical devices with networks that release the antimicrobial agent

Fig. 1. Internal and external stimuli evaluated to trigger ancillary drug release from medical devices and main outcomes expected.

Fig. 2. Main mechanisms explored so far to endow medical devices with self-defensive behavior against biofilm formation. (A) Coatings that switch antimicrobial drug release on/off in response to enzymes and pH changes associated with microbial growth. (B) Contact-killing moieties that activate in the presence of microorganisms. (C) Bioinspired moieties that resemble natural receptors of the microorganisms and transfer the antimicrobial agent through a competitive mechanism.

only if the colonization occurs (Alvarez-Lorenzo et al., 2016; Cyphert and von Recum, 2017; Wei et al., 2019).

Infection-responsive (or bacteria self-defensive) medical devices rely on three main mechanisms: 1) coatings responsive to the changes in enzymes and pH associated with microbial growth; 2) surfaces that expose contact-killing moieties in the presence of the microorganisms; and 3) bioinspired moieties that release the antimicrobial agent through a competitive mechanism with the microorganism wall (Fig. 2). Specific examples are summarized in Table 2.

The design of wound dressings that can simultaneously favor healing and prevent infections has received a great deal of attention as well. For example, electrospun mats of poly(lactic-co-glycolic) acid (PLGA) can degrade faster—and thus release their encapsulated drugs more rapidly—as microorganisms grow and release lipolytic esterases. As demonstrated for *Pseudomonas aeruginosa*, *Staphylococcus aureus* standard strain, and methicillin-resistant *S. aureus* (MRSA1), biofilm formation on electrospun mats causes the hydrolysis of PLGA and thus the release of fusidic acid, which in turn leads to the killing of the bacteria (Said et al., 2011). The benefits of this

approach have been demonstrated both in vitro and in vivo (Said et al., 2012). Also poly-L-lysine coatings have been shown to be degradable by chymotrypsin, showing bacterial infection-dependent release of gentamicin (Xu et al., 2017).

Bacteria growth is also associated with changes in the surrounding pH, which can be exploited as a stimulus to trigger drug release from the medical devices (Pavlukhina et al., 2014). In this regard, layer-by-layer coatings of oppositely charged polymers and antimicrobial agents have been shown to rapidly disassemble in response to the drop in pH that occurs as *Staphylococcus epidermidis* or *Escherichia coli* grow and generate lactic acid and acetic acid, respectively. The films can be designed to not release the drug at pH 7.4, but to efficiently elute the antimicrobial agent as the surroundings become acidic, which causes bacteria eradication (Zhuk et al., 2014). Nevertheless, pH-responsive systems may not discriminate between the drop in pH associated with bacteria growth and that caused by the migration of macrophages to the implantation site after surgery. Further in vivo studies are required to examine these conditions.

Changes in pH also can be exploited to trigger the release of antimicrobial agents immobilized on the device surface. The surface of medical devices can be easily modified with poly(acrylic acid) (PAA) by use of either plasma polymerization or gamma-ray grafting approaches; PAA-grafted chains act as intermediates for binding cationic drugs through strong ionic interactions (Mendes, 2008; Alvarez-Lorenzo et al., 2010). Remarkably, changes in pH in the typical range of microorganism growth may reverse the affinity and thus trigger the release of the drug, as demonstrated for vancomycin and antimicrobial peptides (Ruiz et al., 2008; Muñoz-Muñoz et al., 2012; García-Vargas et al., 2014; Traba and Liang, 2015). In case of the lytic peptide agents, their direct transfer from the device to the bacteria membrane and the increase in their activity as the pH decreases strongly contributes to the inhibition of biofilm formation (Traba and Liang, 2015).

Interestingly, PAA grafts also allow for the spontaneous formation of gold nanoparticles on the surface of the medical devices, which opens the way to near-infrared (NIR) responsive photothermal ablation of biofilm (Cabana et al., 2017). Grafting of cationic polymers has been explored for loading anionic antimicrobial agents (Contreras-García et al., 2011). Also, antimicrobial agents covalently linked to the medical device through labile bonds have shown pH-responsive release in media mimicking bacteria growth (McCoy et al., 2016).

Urease-producing microorganisms cause an increase in the pH of urine, which may lead to salt deposition on the lumen of catheters and their blockage. To prevent this phenomenon, urinary catheters have been coated with a reservoir containing bacteriophages with a sealing layer of pH-responsive Eudragit S100. The coating is stable in the presence of urease-negative bacteria but provides a burst release of bacteriophages in the presence of *Proteus mirabilis*, which in turn causes a significant decrease in bacteria cells and doubles the time required until blockage (Milo et al., 2017).

Using a similar approach, pH-responsive coatings have been recently developed to act as infection-responsive therapeutic materials. Layers of PAA and chitosan-trapping ciprofloxacin, sealed with Eudragit S100, have been designed to undergo distinct chromatic color transitions from blue to purple and red as the pH becomes more alkaline, acting as a sensor for early infection and also as a warning of the risk of

TABLE 2

Examples of infection-responsive antimicrobial-eluting medical devices

Drug-Eluting Medical Device	Triggered Stimulus	Reference
Electrospun mat of PLGA loaded with fusidic acid	Lipolytic esterases released by bacteria	Said et al. (2011, 2012)
Montmorillonite/poly-L-lysine-gentamicin sulfate organic-inorganic hybrid multilayer films	Chymotrypsin released by bacteria	Xu et al. (2017)
Self-assembled coatings of tannic acid with one cationic antibiotic (tobramycin, gentamicin, and polymyxin B)	Drop in pH	Zhuk et al. (2014)
Medical devices grafted at the surface with PAA chains for binding of antimicrobial peptides	Drop in pH	Traba and Liang (2015)
Medical devices grafted at the surface with PAA chains for spontaneous coating with gold nanoparticles	Light responsive (photothermal effect)	Cabana et al. (2017)
Urinary catheter coated with a hydrogel layer of 2-hydroxyethyl methacrylate and vinyl-functionalized nalidixic acid derivatives	Pathogen-induced elevation of urine pH	McCoy et al. (2016)
Urinary catheter coated with an Eudragit S100 coating encapsulating bacteriophages	Pathogen-induced elevation of urine pH	Milo et al. (2017)
Catheter coated with PAA and chitosan comprising a pH (colorimetric) sensor and ciprofloxacin-loaded vesicles and sealed with Eudragit S100	Pathogen-induced elevation of urine pH, and visual indication of early infection by urease-producing bacteria	Zhou et al. (2018)
Ergosterol-coated medical devices for affinity-driven loading of antifungal agents	Competitive displacement of natamycin and nystatin toward the fungi wall	Segura et al. (2014)
Cyclodextrin-decorated gauzes loaded with quorum-sensing inhibitors and vancomycin	Quorum-sensing signaling molecules released by Gram-negative bacteria	Brackman et al. (2016)

PAA, poly(acrylic acid); PLGA, poly(lactic-co-glycolic) acid.

blockage. Moreover, the pH-responsive release of the antimicrobial agent notably decreased bacterial growth in an in vitro infected bladder model (Zhou et al., 2018).

A second family of self-defensive materials relies on the design of surfaces that trap microorganisms and kill them through immobilized biocide groups (Luna-Straffon et al., 2014; Huang et al., 2015). Contact-killing surfaces have been prepared that combine the temperature-responsive poly(*N*-isopropylacrylamide) (PNIPAAm) with biocidal quaternary ammonium salts. At 37°C, PNIPAAm brushes are shrunken, and the biocidal groups protrude on the surface. Thus, bacteria that adhere to the surface through hydrophobic interactions are exposed to the biocidal agent. The killed bacteria can be removed from the surface by washing in water at temperature below the low critical solubility temperature of PNIPAAm (Pavluhina et al., 2012). The surface also can be designed to exhibit the opposite performance: oligo(ethylene glycol) methacrylates conjugated with antimicrobial peptides show a swelling-collapse transition at 35°C. Below this temperature, bacteria can freely enter into contact with the peptide, and the bactericide effect occurs. At 37°C, the ethylene glycol moieties predominate, and the material becomes a bacteria repellent (Laloyaux et al., 2010). Also pH-responsive polymer brushes such as poly(2-ethylacrylic acid), poly(2-*n*-propylacrylic acid), and poly(2-*n*-butylacrylic acid) have been shown to exhibit contact-killing capability under acidic conditions (Lu et al., 2015).

The third mechanism relies on bioinspired strategies to host the antimicrobial drug and to trigger its release through a competitive mechanism when the microorganisms are present. The small structural differences between cholesterol (a structural component of mammalian membranes) and ergosterol (present in fungi walls) are the basis of the discovery of a relevant family of antifungal drugs. Polyenes, azols, and allylamines selectively interact with fungi, blocking their growth while remaining innocuous for mammals.

Thus, applying ergosterol on medical devices has been investigated as a way to endow the surface with the capability of hosting therapeutically efficient amounts of antifungal agents and of retaining them at physiologic pH without leakage; the release is triggered when a fungal infection has been mimicked (Segura et al., 2014). Tests performed in the presence of *Candida albicans* showed the fungi-responsive, ergosterol-functionalized devices efficiently inhibited biofilm formation.

A different approach was explored with cyclodextrin-functionalized wound dressing. Cyclodextrins have the ability to host quorum-sensing inhibitors and antimicrobial agents forming inclusion complexes, and they also can host quorum-sensing signaling molecules—that is, the molecules released by bacteria to communicate with each other and develop biofilm (Okano et al., 2016). Thus, cyclodextrin-functionalized gauzes were successfully loaded with hamamelitannin (a quorum-sensing inhibitor) and vancomycin, and then they were exposed to *S. aureus* monospecies biofilm and to *S. aureus* plus *Pseudomonas aeruginosa* mixed biofilm mimicking a chronic wound infection. Relevantly, the loaded gauzes decreased biofilm formation and increased bacteria susceptibility toward vancomycin in both biofilm types. The release of the active ingredients was favored by the presence of the quorum-sensing signaling molecules due to competitive mechanisms for forming inclusion complexes with the cyclodextrins (Brackman et al., 2016).

Drug-Eluting Medical Devices for Smart Regenerative Medicine. In addition to infection prevention, orthopedic implants, vascular grafts, and other medical devices intended for tissue regeneration demand the release of active substances that can mimic the natural cascade that takes places during the natural healing process (Bagherifard, 2017). Strong efforts are being made to create synthetic devices that can stabilize the site of injury, with mechanical properties similar to the tissue to be repaired and an architecture that allows host-cell colonization. Encouraging the adhesion of

TABLE 3
Examples of stimuli-responsive release from scaffolds for regenerative medicine

Drug-Eluting Medical Device	Triggered Stimulus	Reference
NSAID-immobilized hydrogel coating	Inflammation; overexpression of esterases triggers the release of indomethacin	He et al. (2017)
NSAID-immobilized electrospun fibers	Inflammation; overexpression of lipase triggers the release of ibuprofen	Pan et al. (2015)
Fibrin scaffolds containing drug-loaded sonosensitive emulsion droplets	Ultrasound; each droplet releases the drug at specific acoustic pressure	Moncion et al. (2018)
Fibrin scaffolds containing bFGF encapsulated in monodispersed emulsion droplets	In vivo ultrasound triggered release of the growth factor for efficient angiogenesis	Moncion et al. (2017)
Chondroitin sulfate-platelet lysate hydrogel encapsulating magnetic nanoparticles and stem cells	Magnetic field modulates the release of platelet lysate growth factors and, in turn, the tendon- and bone-like matrix synthesis	Silva et al. (2018)
Poly(ethylene glycol) hydrogels cross-linked with metalloproteinase substrates and loaded with angiogenic peptide drugs	Cell-released metalloproteinases for regulation of in vivo angiogenesis	Van Hove et al. (2015)
Fibrin scaffold with heparin-binding growth factors	Cell-produced heparinase for triggering bFGF release and enhancing peripheral nerve regeneration	Sakiyama-Elbert and Hubbell (2000)

bFGF, basic fibroblast growth factor; NSAIDs, nonsteroidal anti-inflammatory drugs.

specific cell types and their further growth should be carefully driven toward efficient regeneration that avoids scarring or unnecessary healing delays (Winkler et al., 2018).

Any injury triggers a healing cascade that involves three phases: inflammation, proliferation, and maturation, with the participation of different cells. Migration of inflammatory cells is essential for healing because they not only remove bacteria and foreign materials but also release critical enzymes and cytokines for the subsequent phases. However, an excessive, prolonged inflammation may delay the healing, degrade the scaffold, and provoke fibrosis and scarring. Thus, the inflammation-triggered release of anti-inflammatory drugs has been explored as a way of recapitulating natural tissue regeneration. For example, the covalent grafting of nonsteroidal anti-inflammatory drugs (NSAIDs) via ester groups to hydrogel coatings or electrospinnable components has been shown to be useful in regulating NSAID release as a function of overexpressed esterases (Pan et al., 2015; He et al., 2017) (Table 3).

The next regeneration steps require the sequential release of adequate growth factors for cell proliferation and differentiation. Thus, a variety of strategies are being explored for, commonly, dual delivery of growth factors at different time points or release rates (Izadifar et al., 2015). Although most approaches rely on coatings that encapsulate a given growth factor and release it at a preestablished rate, some evidence of the potential of stimuli-responsive release has been already published (Bruggeman et al., 2018). The relevant examples are summarized in Table 3. External modulation of the release can be achieved by engineering acoustically responsive scaffolds; the scaffolds contain different growth factors in differently designed sonosensitive emulsion droplets, and each droplet releases the content at different acoustic pressures. Thus, precise spatiotemporal control of the release of each growth factor is possible (Moncion et al., 2018). The feasibility of this approach has been already demonstrated in vivo (Moncion et al., 2017). Release that is responsive to magnetic fields has been observed for hydrogels encapsulating magnetic particles and platelet lysates: the application of an external magnetic field can modulate the release of the growth factors, which in turn determine cell expression and the synthesis of tendon- and bone-like matrices (Silva et al., 2018).

Recent research has focused on cell-responsive remodeling of the scaffolds in such a way that specific cell inputs may trigger the release of the adequate growth factor at each time (Murphy and Lampe, 2015). Metalloproteinases released by the cells can regulate the degradation of certain scaffold components and thus the release of encapsulated active substances. Metalloproteinases can also break the labile bonds of growth factors tethered to the scaffold (Van Hove et al., 2015). Also, cell-produced heparinase has been evaluated as a stimulus for the release of growth factors bound to the scaffold through heparin moieties. Heparin has a high affinity for many growth factors, and the dissociation (passive release) is quite slow under physiologic conditions (Martino et al., 2013; Vulic and Shoichet, 2014). Thus, it has been shown that cells may mediate much faster release of the growth factors, which in turn determine the subsequent cell development (Sakiyama-Elbert and Hubbell, 2000).

Foreseeably, the advent of 3D printing technologies makes the design of medical devices with precise locations for active molecules and responsive materials to construct truly dynamic, cell-responsive, or externally activated scaffolds in the near future (Nadgorny and Ameli, 2018).

Mechanically Activated Drug Release. Medical devices inserted or implanted in the body are subjected to physiologic stress and are also susceptible to the action of externally applied forces. A variety of strategies have been explored to trigger drug release using the common mechanical stimuli of compression, tension, and shear (Fig. 3). Physiologic mechanical stimuli and the principles behind the design of mechano-responsive drug delivery systems have been recently reviewed elsewhere (Wang et al., 2017), and relevant examples are summarized in Table 4.

Compressive medical devices are formed by elastomers (viscoelastic materials) that withstand compressive loadings. Compression may allow the release of a certain amount of drug through a squeezing-like mechanism. For example, wound dressings that elute hydrocortisone in response to mechanical stimuli have been designed from alginate hydrogels bearing grafted cyclodextrins. The responsiveness has been attributed to changes in the conformation of the cyclodextrin cavity and the hydrogel network as function of the pressure, which impels the release of the drug from the

Fig. 3. Magnitude of the physiologic and external forces that can be exerted on medical devices. Data taken from Wang et al. (2017).

cyclodextrin cavity and thus accelerates the diffusion out of the hydrogel (Tan et al., 2015). Also, soft contact lenses containing either drugs or comfort ingredients are being designed to release these hydrophilic components toward the cornea surface during blinking (Galante et al., 2015). The pressure of the eyelid on the hydrogel surface combined with the shear stress (dragging components from the contact lens surface) may allow for a pulsate release of the lubricating macromolecules, making wearing the lenses more comfortable and minimizing the risk of dry eye symptoms (Alvarez-Lorenzo et al., 2019).

Tension forces are typical of stents. Several layered composite systems have been reported useful for achieving tension-driven drug release. Stretching of polyelectrolyte films can open nanopores, which act as nanovalves that allow the exit of the drug but close when the film is at rest (Mertz et al., 2007). Similarly, drug-loaded polymer layers coated with a thin titanium layer develop micro-sized cracks when subjected to external tensile strains. The crack area is proportional to the applied strain, and the cracks perform as channels for drug release (Jeon et al., 2018). A different strategy relies on the coating of esophageal stents with superhydrophobic multilayers containing drug-loaded microparticles; the crack propagation of the superhydrophobic coating can be triggered by physiologic forces that facilitate the entrance of the release medium in the coating, thus releasing the drug from the microparticles. The release of both hydrophobic and hydrophilic drugs has been shown to be dependent on the applied strains (Wang et al., 2016, 2018).

Also, stretching may accelerate the release of antimicrobial agents from hydrogels prepared with cyclodextrin monomers. Once again, the deformation of the cyclodextrin cavity drives the release of the previously encapsulated drug molecule

(Ballance et al., 2018). Intriguingly, deformable catheters have been tested for the removal of preformed biofilms using strain forces. *C. albicans* biofilms have been detached from prototypes by selectively inflating the inner chambers, which causes strain on the surface (Maskarinec et al., 2018).

Shear-forces are particularly relevant in the cardiovascular system, and large increases in shearing occur when the vessels become narrow due to physiologic or pathologic events (e.g., atherosclerotic plaques or clots) (Saxer et al., 2013). Indeed, direct correlations between sirolimus release from PLGA films and flow rate of the medium have been found, which may have an impact on DES (Zheng et al., 2017). Nevertheless, much knowledge is still required to reproduce in vitro biorelevant conditions of blood flow (Reviakine et al., 2017).

Electric-Responsive Release. Natural mechanical stimuli can be transformed into electrical stimuli that trigger drug release from a medical device. As a proof of concept, disposable gastric lavage tubes were coated with a piezoelectric network made of poly(vinylidene fluoride-co-hexafluoropropylene) and reduced graphene fillers (PEI-rGO/PVDF-HFP). On these were subsequently deposited a polyamidoamine (PAMAM) dendrimer able to host a variety of drugs, including the antiemetic metoclopramide. Pressure on the gastric lavage tube mimicking human swallowing force (7–10 kPa) was transformed by the piezoelectric network into an electrostatic field (2.7 V) to accelerate drug release. The purpose was the attenuation of nausea to facilitate the intubation process itself. The release rate under the mechanical stimulus was approximately 2-fold the rate recorded at rest. In addition to the wavelike motion of the esophagus, manual deformation of the external portion of the gastric tube caused a similar effect on drug release, and the generated voltages remained in the safe interval for the human body (Zhang et al., 2018).

A different approach consists in exploiting the electrical fields generated by some implantable medical devices during their normal functioning. For example, cochlear implants restore a functional level of hearing to profoundly deaf individuals by means of the electrical stimulation of spiral ganglion neurons. The device involves an electrode array that is implanted into the scala tympani of the cochlea. However, the continuous electrical discharges to activate the central auditory pathways may exacerbate the loss of more hair cells (responsible for the sensorineural deafness), causing the apoptosis of more neurons. This untoward effect may be solved by coating the electrodes with a conductive polymer layer containing therapeutic neurotrophins. The generated electrical stimulus increases the release of the neurotrophic proteins, increasing

TABLE 4
Examples of mechanically activated drug release from medical devices

Drug-Eluting Medical Device	Triggered Stimulus	Reference
Hydrocortisone-loaded alginate-cyclodextrin hydrogels	Manual compression	Tan et al. (2015)
Drug-loaded contact lenses	Eyelid compression	Galante et al. (2015)
Stents coated with drug-loaded polyelectrolyte films that act as pressure-responsive nanovalves	Tension	Mertz et al. (2007)
Drug-loaded polyurethane coated with a thin titanium metal layer that develops micro-crack under strain	Tension	Jeon et al. (2018)
Esophageal stents coated with a superhydrophobic layer embedding drug-loaded microparticles	Tension	Wang et al. (2016, 2018)
Polyacrylamide-cyclodextrin hydrogels loaded with quinine	Tension	Ballance et al. (2018)
Sirolimus-loaded PLGA coating	Shearing	Zheng et al. (2017)

PLGA, poly(lactic-co-glycolic) acid.

the biocompatibility (Richardson et al., 2009; Thompson et al., 2010, 2011).

Also, cochlear implants have been combined with gene therapy to stimulate spiral ganglion neurite regeneration. The electrode array was arranged to create a close-field electroporation for efficient transduction of adjacent mesenchymal stem cells. The regenerated neurites improved the auditory response (Pinyon et al., 2014).

Other Stimuli. As mentioned with biofilm eradication, immobilization of gold nanoparticles on medical devices allows exploiting their NIR sensitiveness. Therefore, irradiating with an external source of NIR may cause local heating, useful for direct thermal ablation of cells (tumor cells, proliferative cells, bacteria) but also for the controlled release of drugs encapsulated in temperature-responsive materials. This strategy has been investigated for esophageal stents implanted to prevent tumor recurrence with

combined gold nanoturfs and doxorubicin (Fig. 4) (Lee et al., 2018).

Finally, vitamin C has been shown to be useful for deactivating the adhesion of dressings to wounds to facilitate their peeling from damaged skin without causing a secondary trauma. Such vitamin C responsiveness relies on its capability to disassemble the protein supramolecular structures contained in the wound dressings (Zhao et al., 2018). This capability could be also exploited for triggering the release of encapsulated drugs.

Conclusions

Medical devices that can precisely regulate the time at which the ancillary drug should be released offer undoubted advantages over devices designed for a preestablished release rate. The amount of drug that can be hosted by the medical

Fig. 4. Structure and performance of an esophageal stent coated with a nanoturf structure containing gold (Au) and doxorubicin (DOX) for combining thermotherapy and chemotherapy. (A) Near-infrared (NIR) responsiveness of the Au coating triggers localized increase in temperature while DOX is being released. (B) SEM images of pristine (left), DOX/Au-coated (middle), and partial drug release (right) nanoturf structures, after incubation in PBS solution for 6 hours. Scale bar: 1 μm . (C) Appearance and surface structure of a nitinol wire stent coated with the nanoturf structures. (D) The esophageal stent covered with an esophagus-mimicking organoid tube prepared for subdermal implantation. (E) TUNEL stains of esophagus-mimicking organoid tubes treated with the nanoturf esophageal stent containing only Au (left) or DOX and Au (right) after NIR irradiation in vivo. Live cells are shown in blue and apoptotic cells in brown. Scale bar: 400 μm . Reprinted with permission from Lee et al. (2018). Copyright (2018) American Chemical Society.

devices is limited (because of limited affinity and also to avoid changes in bulk properties), so regulating the moment at which the drug is delivered is critical for maximizing its prophylactic/therapeutic performance. Smart drug-eluting medical devices have benefited from the knowledge gathered on stimuli-responsive drug nanocarriers.

Additional specific stimuli can be exploited in the case of medical devices. Cell-triggering release of growth factors from orthopedic implants may determine the fate of both the cells and the implant, allowing for optimized healing. Or natural physical forces exerted onto the medical device can directly, or by previous transformation into an electric field, act as efficient stimuli to release drugs that can either minimize untoward reactions (e.g., emesis) or help restoring natural functions (e.g., hearing).

Advances in materials science and pharmaceutical technology together with deeper knowledge about the physiologic variables that can serve as stimuli make foreseeable upgraded medical devices that are more sensitive and robust in the release response and may even have theranostic capabilities. Such devices could play a key role in the health care system in the near future.

The incorporation of drugs into medical devices to create device-led combination products adds complexity to the regulation pathway, compared with solely medical device products. Nevertheless, the efforts that are being made by the regulatory agencies to clarify the premarket pathways are very valuable (Office of Combination Products, 2019).

Authorship Contributions

Performed data analysis: Alvarez-Lorenzo, Concheiro.

Wrote or contributed to the writing of the manuscript: Alvarez-Lorenzo, Concheiro.

References

- Acharya G and Park K (2006) Mechanisms of controlled drug release from drug-eluting stents. *Adv Drug Deliv Rev* **58**:387–401.
- Alvarez-Lorenzo C, Anguiano-Igea S, Varela-García A, Vivero-Lopez M, and Concheiro A (2019) Bioinspired hydrogels for drug-eluting contact lenses. *Acta Biomater* **84**: 49–62.
- Alvarez-Lorenzo C, Bucio E, Burillo G, and Concheiro A (2010) Medical devices modified at the surface by gamma-ray grafting for drug loading and delivery. *Expert Opin Drug Deliv* **7**:173–185.
- Alvarez-Lorenzo C and Concheiro A (2013) Drug/medical device combination products with stimuli-responsive eluting surface, in *Smart Materials for Drug Delivery* (Alvarez-Lorenzo C and Concheiro A eds) **vol. 2**, pp 313–348, RSC Smart Materials, Cambridge, UK.
- Alvarez-Lorenzo C and Concheiro A (2014) Smart drug delivery systems: from fundamentals to the clinic. *Chem Commun (Camb)* **50**:7743–7765.
- Alvarez-Lorenzo C, Garcia-Gonzalez CA, Bucio E, and Concheiro A (2016) Stimuli-responsive polymers for antimicrobial therapy: drug targeting, contact-killing surfaces and competitive release. *Expert Opin Drug Deliv* **13**:1109–1119.
- Alvarez-Lorenzo C, García-González CA, and Concheiro A (2017) Cyclodextrins as versatile building blocks for regenerative medicine. *J Control Release* **268**:269–281.
- Anderson JM (2001) Biological responses to materials. *Annu Rev Mater Res* **31**: 81–110.
- Antony GJM, Jarali CS, Aruna ST, and Raja S (2017) Tailored poly(ethylene) glycol dimethacrylate based shape memory polymer for orthopedic applications. *J Mech Behav Biomed Mater* **65**:857–865.
- Athans V, Veve MP, and Davis SL (2017) Trowels and tribulations: review of antimicrobial-impregnated bone cements in prosthetic joint surgery. *Pharmaco-therapy* **37**:1565–1577.
- Bagherifard S (2017) Mediating bone regeneration by means of drug eluting implants: from passive to smart strategies. *Mater Sci Eng C* **71**:1241–1252.
- Ballance WC, Seo Y, Baek K, Chalifoux M, Kim D, and Kong H (2018) Stretchable, anti-bacterial hydrogel activated by large mechanical deformation. *J Control Release* **275**:1–11.
- Bhide SA and Nutting CM (2010) Recent advances in radiotherapy. *BMC Med* **8**:25.
- Bhusal P, Harrison J, Sharma M, Jones DS, Hill AG, and Svirskis D (2016) Controlled release drug delivery systems to improve post-operative pharmacotherapy. *Drug Deliv Transl Res* **6**:441–451.
- Brackman G, Garcia-Fernandez MJ, Lenoir J, De Meyer L, Remon JP, De Beer T, Concheiro A, Alvarez-Lorenzo C, and Coenye T (2016) Dressings loaded with cyclodextrin-hamamelitannin complexes increase *Staphylococcus aureus* susceptibility toward antibiotics both in single as well as in mixed biofilm communities. *Macromol Biosci* **16**:859–869.
- Bruggeman KF, Williams RJ, and Nisbet DR (2018) Dynamic and responsive growth factor delivery from electrospun and hydrogel tissue engineering materials. *Adv Healthc Mater* **7**:1700836.
- Cabana S, Lecona-Vargas CS, Meléndez-Ortiz HI, Contreras-García A, Barbosa S, Taboada P, Magariños B, Bucio E, Concheiro A, and Alvarez-Lorenzo C (2017) Silicone rubber films functionalized with poly(acrylic acid) nanobrushes for immobilization of gold nanoparticles and photothermal therapy. *J Drug Deliv Sci Technol* **42**:245–254.
- Concheiro A and Alvarez-Lorenzo C (2013) Chemically cross-linked and grafted cyclodextrin hydrogels: from nanostructures to drug-eluting medical devices. *Adv Drug Deliv Rev* **65**:1188–1203.
- Contreras-García A, Bucio E, Brackman G, Coenye T, Concheiro A, and Alvarez-Lorenzo C (2011) Biofilm inhibition and drug-eluting properties of novel DMAEMA-modified polyethylene and silicone rubber surfaces. *Biofouling* **27**: 123–135.
- Couto DS, Perez-Breva L, Saraiva P, and Cooney CL (2012) Lessons from innovation in drug-device combination products. *Adv Drug Deliv Rev* **64**:69–77.
- Cyphert EL and von Recum HA (2017) Emerging technologies for long-term antimicrobial device coatings: advantages and limitations. *Exp Biol Med (Maywood)* **242**:788–798.
- De Angelis G, Murthy A, Beyersmann J, and Harbarth S (2010) Estimating the impact of healthcare-associated infections on length of stay and costs. *Clin Microbiol Infect* **16**:1729–1735.
- Fielding JE (1999) Public health in the twentieth century: advances and challenges. *Annu Rev Public Health* **20**:xiii–xxx.
- Flatt CC, Warren-Morris D, Turner SD, and Chan JT (2008) Effects of a stannous fluoride-impregnated dental floss on in vivo salivary fluoride levels. *J Dent Hyg* **82**:19.
- Galante R, Paradiso P, Moutinho MG, Fernandes AI, Mata JLG, Matos APA, Colaço R, Saramago B, and Serro AP (2015) About the effect of eye blinking on drug release from pHEMA-based hydrogels: an in vitro study. *J Biomat Sci Polym* **26**: 235–251.
- García-Vargas M, González-Chomón C, Magariños B, Concheiro A, Alvarez-Lorenzo C, and Bucio E (2014) Acrylic polymer-grafted polypropylene sutures for covalent immobilization or reversible adsorption of vancomycin. *Int J Pharm* **461**:286–295.
- He M, Wang Q, Shi Z, Xie Y, Zhao W, and Zhao C (2017) Inflammation-responsive self-regulated drug release from ultrathin hydrogel coating. *Colloids Surf B Biointerfaces* **158**:518–526.
- Heath G and Colburn WA (2000) An evolution of drug development and clinical pharmacology during the 20th century. *J Clin Pharmacol* **40**:918–929.
- Holmes DR Jr (2003) State of the art in coronary intervention. *Am J Cardiol* **91** (3A): 50A–53A.
- Hong B, Winkel A, Ertl P, Stumpp SN, Schwabe K, Stiesch M, and Krauss JK (2018) Bacterial colonisation of suture material after routine neurosurgical procedures: relevance for wound infection. *Acta Neurochir (Wien)* **160**:497–503.
- Huang CJ, Chen YS, and Chang Y (2015) Counterion-activated nanoactuator: reversibly switchable killing/releasing bacteria on polycation brushes. *ACS Appl Mater Interfaces* **7**:2415–2423.
- Huang Y, Ng HCA, Ng XW, and Subbu V (2014) Drug-eluting biostable and erodible stents. *J Control Release* **193**:188–201.
- Ikeda M, Tanida T, Yoshii T, Kurotani K, Onogi S, Urayama K, and Hamachi I (2014) Installing logic-gate responses to a variety of biological substances in supramolecular hydrogel-enzyme hybrids. *Nat Chem* **6**:511–518.
- Iqbal J, Gunn J, and Serruys PW (2013) Coronary stents: historical development, current status and future directions. *Br Med Bull* **106**:193–211.
- Izadifar M, Haddadi A, Chen X, and Kelly ME (2015) Rate-programming of nanoparticulate delivery systems for smart bioactive scaffolds in tissue engineering. *Nanotechnology* **26**:012001.
- Jeon H, Kim MS, Hong SK, Cho SJ, and Lim G (2018) Tensile strain-controlled drug delivery system based on a cracked metal structure. *Sensor Actuator B Chem* **270**: 64–71.
- Jones GL, Russell AD, Caliskan Z, and Stickler DJ (2005) A strategy for the control of catheter blockage by crystalline *Proteus mirabilis* biofilm using the antibacterial agent triclosan. *Eur Urol* **48**:838–845.
- King JD, Hamilton DH, Jacobs CA, and Duncan ST (2018) The hidden cost of commercial antibiotic-loaded bone cement: a systematic review of clinical results and cost implications following total knee arthroplasty. *J Arthroplasty* **33**: 3789–3792.
- Kirsh D (August 6, 2018) The 10 most innovative medical devices of 2018. Medical Design & Outsourcing, <https://www.medicaldesignandoutsourcing.com/10-most-innovative-medical-devices-2018/>.
- Kommineni N, Saka R, Khan W, and Domb AJ (2018) Non-polymer drug-eluting coronary stents. *Drug Deliv Transl Res* **8**:903–917.
- Konishi A, Ho M, Shirai Y, and Shirato H (2018) First approval of improved medical device conditional on use-result survey in Japan—regulatory review of polymer-free drug-coated biofreedom coronary stent. *Circ J* **82**:1487–1490.
- Laloyaux X, Fautré E, Blin T, Purohit V, Lepince J, Jouenne T, Jonas AM, and Glinel K (2010) Temperature-responsive polymer brushes switching from bactericidal to cell-repellent. *Adv Mater* **22**:5024–5028.
- Lee DH and de la Torre Hernandez JM (2018) The newest generation of drug-eluting stents and beyond. *Eur Cardiol* **13**:54–59.
- Lee EJ, Huh BK, Kim SN, Lee JY, Park CG, Mikos AG, and Choy YB (2017) Application of materials as medical devices with localized drug delivery capabilities for enhanced wound repair. *Prog Mater Sci* **89**:392–410.
- Lee S, Hwang G, Kim TH, Kwon SJ, Kim JU, Koh K, Park B, Hong H, Yu KJ, Chae H, et al. (2018) On-demand drug release from gold nanoturf for a thermo- and chemotherapeutic esophageal stent. *ACS Nano* **12**:6756–6766.

- Lu Y, Wu Y, Liang J, Libera MR, and Sukhishvili SA (2015) Self-defensive antibacterial layer-by-layer hydrogel coatings with pH-triggered hydrophobicity. *Biomaterials* **45**:64–71.
- Luna-Straffon MA, Contreras-García A, Brackman G, Coenye T, Concheiro A, Alvarez-Lorenzo C, and Bucio E (2014) Wound debridement and antibiofilm properties of gamma-ray DMAEMA-grafted onto cotton gauzes. *Cellulose* **21**: 3767–3779.
- Martino MM, Briquez PS, Ranga A, Lutolf MP, and Hubbell JA (2013) Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. *Proc Natl Acad Sci USA* **110**: 4563–4568.
- Maskarinec SA, Parlak Z, Tu Q, Levering V, Zauscher S, López GP, Fowler VG Jr, and Perfect JR (2018) On-demand release of *Candida albicans* biofilms from urinary catheters by mechanical surface deformation. *Biofouling* **34**:595–604.
- Matsuhisa H, Oshima Y, Maruo A, Hasegawa T, Tanaka A, Noda R, Iwaki R, Matsushima S, Tanaka T, and Kido S (2014) Pacing therapy in children. *Circ J* **78**:2972–2978.
- McCoy CP, Irwin NJ, Brady C, Jones DS, Carson L, Andrews GP, and Gorman SP (2016) An infection-responsive approach to reduce bacterial adhesion in urinary biomaterials. *Mol Pharm* **13**:2817–2822.
- McLaren AC (2004) Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. *Clin Orthop Relat Res* **427**:101–106.
- McVenes R and Stokes K (2016) Steroid-releasing lead, in *Drug-Device Combinations for Chronic Diseases* (Lyu SP and Siegel R eds) pp 119–141, John Wiley & Sons, Hoboken, NJ.
- Mendes PM (2008) Stimuli-responsive surfaces for bio-applications. *Chem Soc Rev* **37**:2512–2529.
- Mertz D, Hemmerlé J, Mutterer J, Ollivier S, Voegel JC, Schaaf P, and Lavallo P (2007) Mechanically responding nanovalves based on polyelectrolyte multilayers. *Nano Lett* **7**:657–662.
- Milo S, Hathaway H, Nzakizwanayo J, Alves DR, Pérez Esteban P, Jones BV, and Jenkins ATA (2017) Prevention of encrustation and blockage of urinary catheters by *Proteus mirabilis* via pH-triggered release of bacteriophage. *J Mater Chem B* **5**:5403–5411.
- Moncion A, Lin M, Kripfgans OD, Franceschi RT, Putnam AJ, and Fabiilli ML (2018) Sequential payload release from acoustically-responsive scaffolds using focused ultrasound. *Ultrasound Med Biol* **44**:2323–2335.
- Moncion A, Lin M, O'Neill EG, Franceschi RT, Kripfgans OD, Putnam AJ, and Fabiilli ML (2017) Controlled release of basic fibroblast growth factor for angiogenesis using acoustically-responsive scaffolds. *Biomaterials* **140**:26–36.
- Muñoz-Muñoz F, Ruiz JC, Alvarez-Lorenzo C, Concheiro A, and Bucio E (2012) Temperature- and pH- sensitive interpenetrating polymer networks grafted on PP: cross-linking irradiation dose as a critical variable for the performance as vancomycin-eluting systems. *Radiat Phys Chem* **81**:531–540.
- Murphy NP and Lampe KJ (2015) Mimicking biological phenomena in hydrogel based biomaterials to promote dynamic cellular responses. *J Mater Chem B* **3**: 7867–7880.
- Nadgorny M and Ameli A (2018) Functional polymers and nanocomposites for 3D printing of smart structures and devices. *ACS Appl Mater Interfaces* **10**: 17489–17507.
- Nibourg LM, Gelens E, Kuijter R, Hooymans JMM, van Kooten TG, and Koopmans SA (2015) Prevention of posterior capsular opacification. *Exp Eye Res* **136**:100–115.
- Office of Combination Products (February 2019) Principles of Premarket Pathways for Combination Products: Guidance for Industry and FDA Staff [Draft Guidance], U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. <https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM630458.pdf>.
- Okano C, Nasuno E, Iimura K, and Kato N (2016) Cyclodextrin-immobilized microspheres for uptake of the quorum-sensing signaling molecule N-acylhomoserine lactone. *J Appl Polym Sci* **133**:43198.
- Oliver K, Seddon A, and Trask RS (2016) Morphing in nature and beyond: a review of natural and synthetic shape-changing materials and mechanisms. *J Mater Sci* **51**: 10663–10689.
- Pan G, Liu S, Zhao X, Zhao J, Fan C, and Cui W (2015) Full-course inhibition of biodegradation-induced inflammation in fibrous scaffold by loading enzyme-sensitive prodrug. *Biomaterials* **53**:202–210.
- Pavluhina S, Zhuk I, Mentbayeva A, Rautenberg E, Chang W, Yu X, van de Belt-Gritter B, Busscher HJ, van der Mei HC, and Sukhishvili SA (2014) Small-molecule-hosting nanocomposite films with multiple bacteria-triggered responses. *NPG Asia Mater* **6**:e121.
- Pavluhina SV, Kaplan JB, Xu L, Chang W, Yu X, Madhyastha S, Yakandawala N, Mentbayeva A, Khan B, and Sukhishvili SA (2012) Noneluting enzymatic anti-biofilm coatings. *ACS Appl Mater Interfaces* **4**:4708–4716.
- Percival SL, Suleman L, Vuotto C, and Donelli G (2015) Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control. *J Med Microbiol* **64**:323–334.
- Pinyon JL, Tardos SF, Froud KE, Y Wong AC, Tompson IT, Crawford EN, Ko M, Morris R, Klugmann M, and Housley GD (2014) Close-field electroporation gene delivery using the cochlear implant electrode array enhances the bionic ear. *Sci Transl Med* **6**:233ra54.
- Raval A and Parikh J (2010) Mechanism of controlled release kinetics from medical devices. *Braz J Chem Eng* **27**:211–225.
- Rémy B, Mion S, Plener L, Elias M, Chabrière E, and Daudé D (2018) Interference in bacterial quorum sensing: a biopharmaceutical perspective. *Front Pharmacol* **9**: 203.
- Reviakine I, Jung F, Braune S, Brash JL, Latour R, Gorbet M, and van Oeveren W (2017) Stirred, shaken, or stagnant: what goes on at the blood-biomaterial interface. *Blood Rev* **31**:11–21.
- Richardson RT, Wise AK, Thompson BC, Flynn BO, Atkinson PJ, Fretwell NJ, Fallon JB, Wallace GG, Shepherd RK, Clark GM, et al. (2009) Polypyrrole-coated electrodes for the delivery of charge and neurotrophins to cochlear neurons. *Biomaterials* **30**:2614–2624.
- Ruiz JC, Alvarez-Lorenzo C, Taboada P, Burillo G, Bucio E, De Pijck K, Nelis HJ, Coenye T, and Concheiro A (2008) Polypropylene grafted with smart polymers (PNIPAAm/PAAc) for loading and controlled release of vancomycin. *Eur J Pharm Biopharm* **70**:467–477.
- Said SS, Aloufy AK, El-Halfawy OM, Boraei NA, and El-Khordagui LK (2011) Antimicrobial PLGA ultrafine fibers: interaction with wound bacteria. *Eur J Pharm Biopharm* **79**:108–118.
- Said SS, El-Halfawy OM, El-Gowelli HM, Aloufy AK, Boraei NA, and El-Khordagui LK (2012) Bioburden-responsive antimicrobial PLGA ultrafine fibers for wound healing. *Eur J Pharm Biopharm* **80**:85–94.
- Sakiyama-Elbert SE and Hubbell JA (2000) Development of fibrin derivatives for controlled release of heparin-binding growth factors. *J Control Release* **65**: 389–402.
- Sanchez-Rexach E, Meaurio E, and Sarasua JR (2017) Recent developments in drug eluting devices with tailored interfacial properties. *Adv Colloid Interface Sci* **249**: 181–191.
- Saxer T, Zumbuehl A, and Müller B (2013) The use of shear stress for targeted drug delivery. *Cardiovasc Res* **99**:328–333.
- Segura T, Puga AM, Burillo G, Llovo J, Brackman G, Coenye T, Concheiro A, and Alvarez-Lorenzo C (2014) Materials with fungi-bioinspired surface for efficient binding and fungi-sensitive release of antifungal agents. *Biomacromolecules* **15**: 1860–1870.
- Silva ED, Babo PS, Costa-Almeida R, Domingues RMA, Mendes BB, Paz E, Freitas P, Rodrigues MT, Granja PL, and Gomes ME (2018) Multifunctional magnetic-responsive hydrogels to engineer tendon-to-bone interface. *Nanomedicine* **14**: 2375–2385.
- Simard T, Hibbert B, Ramirez FD, Froeschl M, Chen Y-X, and O'Brien ER (2014) The evolution of coronary stents: a brief review. *Can J Cardiol* **30**:35–45.
- Singha P, Locklin J, and Handa H (2017) A review of the recent advances in antimicrobial coatings for urinary catheters. *Acta Biomater* **50**:20–40.
- Tan L, Li J, Liu Y, Zhou H, Zhang Z, and Deng L (2015) Synthesis and characterization of β -cyclodextrin-conjugated alginate hydrogel for controlled release of hydrocortisone acetate in response to mechanical stimulation. *J Bioact Compat Polym* **30**:584–599.
- Teo AJT, Mishra A, Park I, Kim YJ, Park WT, and Yoon YJ (2016) Polymeric biomaterials for medical implants and devices. *ACS Biomater Sci Eng* **2**:454–472.
- Thompson BC, Moulton SE, Richardson RT, and Wallace GG (2011) Effect of the dopant anion in polypyrrole on nerve growth and release of a neurotrophic protein. *Biomaterials* **32**:3822–3831.
- Thompson BC, Richardson RT, Moulton SE, Evans AJ, O'Leary S, Clark GM, and Wallace GG (2010) Conducting polymers, dual neurotrophins and pulsed electrical stimulation—dramatic effects on neurite outgrowth. *J Control Release* **141**:161–167.
- Traba C and Liang JF (2015) Bacteria responsive antibacterial surfaces for indwelling device infections. *J Control Release* **198**:18–25.
- Tummalaipalli M, Anjum S, Kumari S, and Gupta B (2016) Antimicrobial surgical sutures: recent developments and strategies. *Polym Rev* **56**:607–630.
- U.S. Food and Drug Administration (FDA) (November 13, 2017) FDA approves pill with sensor that digitally tracks if patients have ingested their medication. FDA News Release. <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm584933.htm>.
- U.S. Food and Drug Administration (FDA) (January 8, 2018a) Condoms and sexually transmitted diseases: should spermicides be used with condoms? www.fda.gov/forpatients/illness/hiv/aids/ucm126372.htm#should.
- U.S. Food and Drug Administration (FDA) (March 22, 2018b) Is the product a medical device? <https://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/classifyyourdevice/ucm051512.htm>.
- U.S. Food and Drug Administration (FDA) (October 12, 2018c) Combination product definition and combination product types. <https://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm118332.htm>.
- Van Hove AH, Burke K, Antonienko E, Brown E III, and Benoit DS (2015) Enzymatically-responsive pro-angiogenic peptide-releasing poly(ethylene glycol) hydrogels promote vascularization in vivo. *J Control Release* **217**:191–201.
- Vulic K and Shoichet MS (2014) Affinity-based drug delivery systems for tissue repair and regeneration. *Biomacromolecules* **15**:3867–3880.
- Wallace A, Albadawi H, Patel N, Khademhosseini A, Zhang YS, Naidu S, Knutti-nen G, and Oklu R (2017) Anti-fouling strategies for central venous catheters. *Cardiovasc Diagn Ther* **7** (Suppl 3):S246–S257.
- Wang J, Colson YL, and Grinstaff MW (2018) Tension-activated delivery of small molecules and proteins from superhydrophobic composites. *Adv Healthc Mater* **7**: e1701096.
- Wang J, Kaplan JA, Colson YL, and Grinstaff MW (2016) Stretch-induced drug delivery from superhydrophobic polymer composites: use of crack propagation failure modes for controlling release rates. *Angew Chem Int Ed Engl* **55**:2796–2800.
- Wang J, Kaplan JA, Colson YL, and Grinstaff MW (2017) Mechanoresponsive materials for drug delivery: harnessing forces for controlled release. *Adv Drug Deliv Rev* **108**:68–82.
- Wei T, Yu Q, and Chen H (2019) Responsive and synergistic antibacterial coatings: fighting against bacteria in a smart and effective way. *Adv Healthc Mater* **8**: e1801381.
- Wenke JC and Guelcher SA (2011) Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. *Expert Opin Drug Deliv* **8**:1555–1569.
- World Health Organization (WHO) (2011) *Report on the Burden of Endemic Health Care-Associated Infection Worldwide*, World Health Organization, Geneva, http://apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.pdf.
- World Health Organization (WHO) (March 3, 2018) Medical device—full definition. https://www.who.int/medical_devices/full_definition/en/.

- Winkler T, Sass FA, Duda GN, and Schmidt-Bleek K (2018) A review of biomaterials in bone defect healing, remaining shortcomings and future opportunities for bone tissue engineering: the unsolved challenge. *Bone Joint Res* **7**:232–243.
- Xu Q, Li X, Jin Y, Sun L, Ding X, Liang L, Wang L, Nan K, Ji J, Chen H, et al. (2017) Bacterial self-defense antibiotics release from organic-inorganic hybrid multilayer films for long-term anti-adhesion and biofilm inhibition properties. *Nanoscale* **9**: 19245–19254.
- Yetisen AK, Martinez-Hurtado JL, Ünal B, Khademhosseini A, and Butt H (2018) Wearables in medicine. *Adv Mater* **30**:e1706910.
- Yoshida K, Nakajima S, Kawano R, and Onoe H (2018) Spring-shaped stimuli-responsive hydrogel actuator with large deformation. *Sensor Actuator B Chem* **272**: 361–368.
- Zhang Y, An Q, Tong W, Li H, Ma Z, Zhou Y, Huang T, and Zhang Y (2018) A new way to promote molecular drug release during medical treatment: a polyelectrolyte matrix on a piezoelectric-dielectric energy conversion substrate. *Small* **14**: e1802136.
- Zhao J, Qu YC, Chen H, Xu R, Yu Q, and Yang P (2018) Self-assembled proteinaceous wound dressings attenuate secondary trauma and improve wound healing in vivo. *J Mater Chem B* **6**:4645–4655.
- Zheng Q, Chu Z, Li X, Kang H, Yang X, and Fan Y (2017) The effect of fluid shear stress on the in vitro release kinetics of sirolimus from PLGA films. *Polymers* **9**: 618.
- Zhou J, Hou S, Li L, Yao D, Liu Y, Jenkins ATA, and Fan Y (2018) Theranostic infection-responsive coating to in situ detect and prevent urinary catheter blockage. *Adv Mater Interfaces* **5**:1801242.
- Zhuk I, Jariwala F, Attygalle AB, Wu Y, Libera MR, and Sukhishvili SA (2014) Self-defensive layer-by-layer films with bacteria-triggered antibiotic release. *ACS Nano* **8**:7733–7745.
- Zilberman M and Elsnor JJ (2008) Antibiotic-eluting medical devices for various applications. *J Control Release* **130**:202–215.

Address correspondence to: Angel Concheiro, Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia, and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782-Santiago de Compostela, Spain. E-mail: angel.concheiro@usc.es